Simvastatin Tablets

Document Sample
Simvastatin Tablets Powered By Docstoc
					Simvastatin Tablets
Simvastatin Tablets
1. Potent lipid-lowering drugs, for various types of
hypercholesterolemia, hyperlipidemia has a good therapeutic effect;
2. Full retard the process of atherosclerosis;
3. Reduce LDL cholesterol more.
Golden Elephant Price: £¤ 20.00 VIP Price: £¤ 19.60
Market price: £¤ 20.70
Discount: 97 off save: £¤ 0.70
¡¿ ¡¾Company Updates
Note: Please read the instructions carefully and follow the
instructions under the guidance of the use or the purchase and use of
¡¾Drug name¡¿ generic name: simvastatin
Indications 1 .. hyperlipidemia: (1) For primary hypercholesterolemia,
heterozygous familial hypercholesterolemia or mixed hyperlipidemia in
patients with high cholesterol, when diet and other non-drug treatment
not ideal, simvastatin can be used to reduce elevated total
cholesterol, LDL cholesterol, apolipoprotein B and triglycerides. And
simvastatin increased HDL cholesterol, thus reducing low-density
lipoprotein / high density lipoprotein and total cholesterol / HDL
ratio. (2) for homozygous familial hypercholesterolemia patients, when
diet control and non-dietary therapy is unsatisfactory, simvastatin
can be used to reduce elevated total cholesterol, low density
lipoprotein cholesterol and apolipoprotein B. 2. Coronary heart
disease. Coronary heart disease patients, simvastatin for: (1) reduce
the risk of death. (2) reduce coronary heart disease death and
non-fatal myocardial infarction risk. (3) reduction of stroke and
transient ischemic risk. (4) reduce myocardial revascularization
surgery (coronary artery bypass grafting and percutaneous coronary
angioplasty balloon) risk. (5) delay the progress of atherosclerosis,
including new lesions and the occurrence of the whole block.
Dosage 1. Oral: If you need to break apart and take it. (1)
hypercholesterolemia: General began serving daily dose 10mg, Dayton
clothing evening. For mild to moderately elevated cholesterol levels
in patients, before serving as a daily dose of 5mg. For dose
adjustment interval of more than four weeks should be the maximum
daily dose 40mg, Dayton clothing evening. When the low-density
lipoprotein cholesterol levels fell to 75mg/dL (1.94mmol / L) or total
cholesterol level dropped to 140mg/dL (3.6mmol / L) below, should
reduce the dosage of simvastatin. (2), homozygous familial
hypercholesterolemia: results of clinical studies under the control of
homozygous familial hypercholesterolemia patients, it is recommended
simvastatin 40mg / d evening Dayton clothing, or 80mg / d divided
morning and 20mg, 20mg noon taking 40mg three times and in the
evening. Simvastatin lipid-lowering therapy should be combined with
other applications (such as low-density lipoprotein extraction), when
not using these methods can also be simvastatin alone. (3) coronary
heart disease: coronary heart disease patients can take 20mg every
night as the starting dose, dose adjustments, if necessary, refer to
the instructions above (high cholesterol and dosage.) (4)
Collaborative Treatment: simvastatin acid chelating agent alone or
with collaborative applications are valid. Have been taken for the
same drugs in patients with immunosuppressive agents, the recommended
daily dose of simvastatin 10mg. (5) renal dysfunction: the obvious
simvastatin excretion by the kidneys, so patients with moderate renal
insufficiency without dose adjustment; for patients with severe renal
insufficiency (creatinine clearance less than 30ml/min), such as the
use of doses exceeding 10mg per day should be carefully considered and
carefully used.
Adverse reactions of simvastatin was generally well tolerated, most
adverse reactions were mild and transient for. In controlled clinical
trials in less than 2% of patients due to adverse reactions
simvastatin half-way stop. In the control group had clinical trials,
adverse events (divided into possible, suspicious or positive) and the
incidence of drug-related greater than or equal to 1% are: abdominal
pain, constipation, flatulence. Incidence of 0.5% to 0.9% of the
adverse reactions are fatigue, weakness, headache. The report found
that myopathy is rare. The following adverse reactions have been
reported in clinical trials without control groups or post-marketing
applications, such as nausea, diarrhea, rash, indigestion, itching,
hair loss, dizziness, muscle cramps, myalgia, pancreatitis,
paresthesia, peripheral neuropathy, vomiting and anemia,
rhabdomyolysis and hepatitis / jaundice rarely occurs. Include one or
more of the characteristics of the syndrome was rare reports of
allergic reactions such as angioedema, lupus-like syndrome, rheumatic
multiple myalgia, vasculitis, thrombocytopenia, increased eosinophils,
erythrocyte sedimentation rate (ESR) increase, arthritis, arthralgia,
urticaria, photosensitivity, fever, flushing, breathing difficulties
and discomfort. Laboratory findings: serum aminotransferase
significant and sustained increase in the rare case reports. Abnormal
liver function minor or transient. From skeletal muscle part of the
serum creatine kinase (CK) also reported higher situation.
¡¾1¡¿ taboo. For those who are allergic to any ingredient. 2. Active
hepatitis or unexplained sustained elevated serum aminotransferase. 3.
Tetralin phenols and calcium channel blockers mibefradil combined.
Medication¡¿ ¡¾special populations
¡¾Notice¡¿ 1. Patients receiving simvastatin should receive the standard
cholesterol diet before and during treatment to use. 2. Liver
reaction. The drug should be used with caution in the consumption of
alcohol and / or history of liver disease patients. Have active liver
disease or unexplained elevated aminotransferase simvastatin should be
banned. In clinical trials, a small number of patients taking
simvastatin had significant sustained increase in serum
aminotransferase (more than 3 times normal) phenomenon. But after
stopping, the aminotransferase levels can be restored to
pre-treatment, but no jaundice or other clinical symptoms or signs
related to, nor allergies. Recommended treatment for the phenomenon of
aminotransferase in patients with elevated check and pay more
attention should be strengthened. If the patient's aminotransferase
performance has continued to rise, especially aminotransferase more
than 3 times higher than the normal value and maintain continuous,
then should be discontinued. The same with other lipid-lowering drugs,
patients treated with simvastatin moderately elevated aminotransferase
(less than 3 times the normal situation) are also reported. These
changes usually shortly after simvastatin treatment has occurred, but
is generally transient and not accompanied by any symptoms, so do not
stop. 3. Muscle response. Common in patients treated with simvastatin
had creatine kinase (CK, from skeletal muscle) a transient increase
slightly, but no clinical significance. For diffuse muscle pain,
muscle weakness and / or significant creatine kinase (CK) increased
(more than ten times greater than normal) situation should be
considered as myopathy, patients should be asked to explain, if not
found The signs of myopathy should immediately tell the doctor. If it
is found creatine kinase (CK) was significantly increased muscle pain
or diagnosed or suspected, should immediately stop simvastatin
treatment. For acute or serious conditions implied by myopathy and
rhabdomyolysis with acute renal failure caused by secondary patient
should stop the tendency of hydroxyl methyl glutaryl coenzyme A
(HMG-CoA) reductase inhibitor therapy. 4. Eye examination. Even in the
absence of any drug treatment, lens opacity with age will also
increase the incidence of long-term clinical study data showed that
simvastatin has no adverse effect on human lens. 5. Homozygous
hypercholesterolemia families. Since homozygous familial
hypercholesterolemia patients with low-density lipoprotein (LDL)
receptors in the complete lack of reason, simvastatin treatment of
such patients is not ideal. 6. High triacylglycerol blood. Simvastatin
only moderately effective triglyceride lowering, and not suitable for
treatment with elevated triglyceride-based exceptions (such as ¢ñ, ¢ô,
and ¢õ hyperlipidemia). 7. Excessive drinking of alcohol and / or a
past history of liver patients, should be cautious to the FDA.
¡¾Approval number¡¿ Zhunzi H20057473
¡¾Validity¡¿ (to identify the actual purchase of goods subject)
¡¿ ¡¾Manual Revision Date
¡¾Manufacturer¡¿ stone Pharmaceutical Factory in Shantou